Health

SiYi Intelligence Raises Nearly $15 Million in Series A Financing

SHANGHAI, March 6, 2023 /PRNewswire/ -- SiYi Intelligence, an intelligent rehabilitation solution provider, completed nearly15 million US dollars in Series A financing. This round was led by Chengdu Bio-town Equity Investment Fund with participation from existing investor Tao Capital. The company...

2023-03-06 22:05 2241

AnPac Bio-Medical Science Announces US$5 Million Private Placement

NEW YORK, March 6, 2023 /PRNewswire/ -- AnPac Bio-Medical Science Co., Ltd. (Nasdaq: ANPC) ("AnPac Bio," the "Company" or "we"), a company with operations inthe United States and China focused on early cancer screening and detection and plans to enter into the operation of a business-to-business ...

2023-03-06 21:30 3387

HanAll Biopharma's Licensed Partner in China Announces Positive Topline Phase 3 Results for Batoclimab in Myasthenia Gravis

* The trial met its primary endpoint and key secondary endpoints, with a favorable safety profile * Batoclimab is one of the most advanced FcRn inhibitors being developed in Greater China for the treatment of myasthenia gravis SEOUL, South Korea, March 6, 2023 /PRNewswire/ -- HanAll Biopharma...

2023-03-06 20:00 1652

Assure Tech Launches a New Platform - Comprehensive Health Solution

HANGZHOU, China, March 6, 2023 /PRNewswire/ -- With the rapid development of the social economy and the continuous improvement in people's living standard, pets, especially cats and dogs, have gradually become important family members in modern times.World wide, strong demand for pet-related prod...

2023-03-06 18:47 1368

Harbour BioMed Announces Positive Topline Results from Phase III Trial of Batoclimab for Treatment of Generalized Myasthenia Gravis

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China, March 6, 2023 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody therapeutics focusing on oncology and immunol...

2023-03-06 14:27 2261

US proteomics sector set for shake-up as new IonOpticks tech unveiled

IonOpticks to introduce the TS, a fully integrated column heating and interface solution for Thermo Scientific users MELBOURNE, Australia, March 3, 2023 /PRNewswire/ -- IonOpticks, a producer of high-performance chromatography solutions for the global research community, will introduce the new T...

2023-03-03 22:00 3891

Neurophet to unveil new technology for analyzing ARIA side effect at ECR 2023

* Introducing brain imaging analysis solutions including Neurophet AQUA and Neurophet SCALE PET * Unveiling technology to analyze and monitor ARIA, side effect of anti-amyloid antibody drug for Alzheimer's disease SEOUL, South Korea, March 2, 2023 /PRNewswire/ -- Neurophet, an artificial inte...

2023-03-02 22:00 2241

Porton Advanced Collaborates with DanausGT to Accelerate the Development of Gene and Cell Therapy

SUZHOU,China, March 2, 2023 /PRNewswire/ -- Porton Advanced Solutions Ltd. (Porton Advanced) and DanausGT Biotechnology Co., Ltd. (DanausGT) announced on February 27, 2023, a strategic collaboration in gene and cell therapy pipelines to expedite the development of innovative therapeutics.

2023-03-02 20:00 2137

Sanyou Biopharmaceuticals opens Cambridge MA, US office, expanding its business outreach to a central hub of biotech network

CAMBRIDGE, Mass., March 2, 2023 /PRNewswire/ -- Sanyou Biopharmaceuticals, a leading provider of biotech CRDMO services, is opening a new office in Cambridge Innovation Centre, CIC, marking a new era towards the company's rising ambition on serving and collaborating with world's best biotech sta...

2023-03-02 18:00 1706

111 to Announce Fourth Quarter and Fiscal Year 2022 Unaudited Financial Results- Conference Call to Follow

SHANGHAI, March 2, 2023 /PRNewswire/ -- 111, Inc. (NASDAQ: YI) ("111" or the "Company"), a leading tech-enabled healthcare platform company committed to digitally connecting patients with medicine and healthcare services inChina, today announced that it will report its unaudited financial results...

2023-03-02 15:35 2486

ExoCoBio obtained 2 GMP Licenses for Exosome Biopharmaceuticals from Korea MFDS and for Hyaluronic Acid (HA) Dermal Fillers from Brazil ANVISA

* ExoGMP™ is the world's largest exosome manufacturing facility in Osong, South Korea. * Cellosome™ HA fillers are expected to be approved in 2023. * ExoCoBio has all 3 types of GMP clearance for pharmaceuticals, medical devices, & cosmetics. SEOUL, South Korea, March 2, 2023 /PRNewswire/ -...

2023-03-02 14:09 3923

Maternity and Baby Brand Momcozy Launches 'Parachute Care Program' to Support Breastfeeding Journeys

NEW YORK, March 1, 2023 /PRNewswire/ -- Momcozy, the renowned maternity and baby brand endorsed by over 2 million moms globally, has announced the year-long Parachute Care Program  to support more moms' breastfeeding journeys. The brand has kicked off the first ...

2023-03-01 21:00 1864

GenFleet receives EMA approval for phase Ib/II study of GFH925 (KRAS G12C inhibitor) in combination with ERBITUX® (cetuximab) treating patients with advanced NSCLC in first-line setting

SHANGHAI, March 1, 2023 /PRNewswire/ -- GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies in oncology and immunology, announced today that European Medicine Agency (EMA) approved the phase Ib/II study of GFH925 (KRASG12C inhibitor) in combination wit...

2023-03-01 19:00 1939

First in Class, Mabwell Announces the TGA Approval of 9MW3811 for IND

SHANGHAI, Feb. 28, 2023 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with the layout of whole industry chain, announced that its IND application of its self-developed 9MW3811 injection for tumor and pulmonary fibrosis has been approved by the Therapeutic Goods Admi...

2023-02-28 23:00 1824

Oricell Closes $45M Series B1 Financing to Expand Development of Key Products

SHANGHAI, Feb. 28, 2023 /PRNewswire/ -- Oricell Therapeutics Co., Ltd ("Oricell" or "the Company"), aChina-based innovative pharmaceutical company committed to the development of tumor cellular immunotherapeutics, today announced the close of a$45M Series B1 investment round after the completion ...

2023-02-28 21:00 2584

Gracell Biotechnologies to Participate in Oppenheimer 33rd Annual Healthcare Conference

SAN DIEGO Calif., and SUZHOU and SHANGHAI, China, Feb. 28, 2023 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell" or the "Company"), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of...

2023-02-28 21:00 1891

GC Biopharma Signs Agreement with Catalyst Biosciences for the Acquisition of Rare Disease Pipeline in Hematology

* Entered into an acquisition deal of 3 programs YONGIN, South Korea, Feb. 27, 2023 /PRNewswire/ -- GC Biopharma Corp. (006280.KS), a leading provider of biopharmaceutical products inSouth Korea, announced today that it has signed an Asset Purchase Agreement with Catalyst Biosciences (NASDAQ : ...

2023-02-28 08:53 2229

WAT Med initiates collaborative research study with The Ohio State University to test the effectiveness of EmeTerm - neuromodulation technology to manage nausea and vomiting

VANCOUVER, BC, Feb. 27, 2023 /PRNewswire/ -- The study recruits patients who suffer from chronic nausea and vomiting. EmeTerm Explore's antiemetic effectiveness will be tested and measured using subjective responses and objective physiological data from the patients.

2023-02-28 02:15 1735

Eluminex Biosciences Closes $40+ Million Series B Financing to Continue the Development of Innovative Ophthalmic Assets and Recombinant Human Collagen Technology

SUZHOU, China and SAN FRANCISCO, Feb. 27, 2023 /PRNewswire/ -- Eluminex Biosciences (Suzhou) Limited (Eluminex) officially announced today the closing of a Series B financing of over$40 million (USD). Financing was led by Cenova Capital with additional participation from Guangzhou Yuexiu Industri...

2023-02-28 01:00 1961

Gracell Biotechnologies to Report Fourth Quarter 2022 Financials on Monday, March 13, 2023

SAN DIEGO, Calif., and SUZHOU and SHANGHAI, China, Feb. 27, 2023 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell" or the "Company"), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment o...

2023-02-27 21:00 1576
1 ... 110111112113114115116 ... 280